We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Island Pharmaceuticals Limited is a biotechnology business based in Australia. Island Pharmaceuticals shares (ILA) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Island Pharmaceuticals has a market cap (total outstanding shares value) of $25.1 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | $0.2675 - $0.67 |
|---|---|
| 50-day moving average | $0.3341 |
| 200-day moving average | $0.3453 |
| Target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | N/A |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.315
| 1 week (2021-10-14) | -1.56% |
|---|---|
| 1 month (2021-09-21) | -3.08% |
| 3 months (2021-07-21) | 6.78% |
| 6 months (2021-04-21) | -14.86% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | 0% |
| Return on equity TTM | -9999999% |
| Profit margin | 0% |
| Book value | N/A |
| Market capitalisation | $25.1 million |
TTM: trailing 12 months
We're not expecting Island Pharmaceuticals to pay a dividend over the next 12 months.
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; research collaboration agreement with Compounds Australia, a drug library containing approximately four and a half thousand molecules that could be searched for drug re-purposing and pipeline development; cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was founded in 2017 and is based in Camberwell, Australia.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Shares in the wealth management giant have been largely stable in the last 6 months.
Everything we know about the Judo Capital Holdings IPO, plus information on how to buy in.
Everything we know about the Allaggio Group IPO, plus information on how to buy in.
Everything we know about the Larvotto Resources IPO, plus information on how to buy in.
Everything we know about the Vulcan Steel IPO, plus information on how to buy in.
Everything we know about the Artrya IPO, plus information on how to buy in.
Everything we know about the 8 Au IPO, plus information on how to buy in.
Everything we know about the Radiopharm Theranostics IPO, plus information on how to buy in.
The online retailer’s shares have lost more than half their value in the last 12 months.
